19.11.2015,
4103 Zeichen
ad-hoc disclosure transmitted by euro adhoc with the aim of a
Europe-wide distribution. The issuer is solely responsible for the
content of this announcement.
Financial Figures/Balance Sheet/quarterly report 19.11.2015
Full order books allow for continued high level of revenues
Revenues up 12% at EUR 627.5 million
Revenue increase of 10% for 2015
EBIT margin of lower than 6% anticipated for 2015 due to
postponed deliveries
_________________________________________________________________
_____________
|KEY CORPORATE | | | |Change in % |
|FIGURES________|______________|1-9/2015_______|1-9/2014_______|_______________|
|Revenues_______|in_EUR_million|__________627.5|________562.0*)|___________+12%|
| |in EUR million| | | |
|EBIT___________|EUR___________|___________27.6|___________31.6|__________(13%)|
|Net profit for | | | | |
|the_period_____|in_EUR_million|___________21.1|___________24.0|__________(12%)|
|Cash flow from | | | | |
|operating | | | | |
|activities_____|in_EUR_million|_________(67.0)|________(115.0)|______________-|
|Investments____|in_EUR_million|___________17.0|___________22.2|__________(23%)|
|Earnings per | | | | |
|share__________|EUR___________|____________1.5|____________2.6|__________(42%)|
|Employees as of| | | | |
|September_30___|______________|__________3,067|__________2,898|____________+6%|
|Order_intake___|in_EUR_million|__________698.6|__________632.3|___________+10%|
|Order backlog | | | | |
|as of September| | | | |
|30_____________|in_EUR_million|__________846.1|__________760.1|___________+11%|
*) The disclosure of the previous year's figures for 2014 has
been revised as necessitated by the readjustment of segment
reporting.
Revenues The Rosenbauer Group continued its growth in the first
three quarters of 2015. Consolidated revenues increased to EUR 627.5
million (1-9/2014: EUR 562.0 million). The Group's revenues were up
12%, due chiefly to increased deliveries to Arabic countries and
North America as well as to positive currency effects. The
disclosure of the revenues figures for 2014 was also adjusted due to
the review of the criteria for segment reporting.
Result of operations EBIT was lower than last year at EUR 27.6
million (1-9/2014: EUR 31.6 million). The decline in earnings was
influenced mainly by the expenses for the launch of new products and
the Group's appearance at the world's largest trade fair, which
caused other expenses to rise by 20% to EUR 78.8 million. The
intra-year EBIT margin of 4.4% (1-9/2014: 5.6%) therefore fell short
of the long-term target.
Outlook Even though the situation on the fire equipment markets
is not the same all over the world, a slight recovery in overall
demand is nonetheless anticipated. Given the solid development in
incoming orders in recent months and the expanded production
capacity, management is assuming that the current growth will
continue. Rosenbauer still expects to generate a 10% increase in
revenues in 2015. However, as a result of the expenses for the
launch of new products and postponed deliveries, operating earnings
will not change to the same extent and an EBIT margin of lower than
6% is anticipated.
end of announcement euro adhoc
issuer: Rosenbauer International AG
Paschingerstrasse 90
A-4060 Leonding
phone: +43(0)732 6794 568
FAX: +43(0)732 6794 89
mail: ir@rosenbauer.com
WWW: www.rosenbauer.com
sector: Machine Manufacturing
ISIN: AT0000922554
indexes: WBI, ATX Prime
stockmarkets: free trade: Berlin, Stuttgart, official market:
Wien language: English
Digital press kit:
http://www.ots.at/pressemappe/2916/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #637: Egalite Addiko und Marinomed, AT&S nach 2 Monaten zurück, 19 Jahre RBI an der Börse, Strabag top
Rosenbauer
Akt. Indikation: 29.30 / 30.20
Uhrzeit: 23:00:44
Veränderung zu letztem SK: 0.17%
Letzter SK: 29.70 ( -0.67%)
Bildnachweis
1.
Gerda Königstorfer (Rosenbauer) - Gabriele Fröhlich, Akademie Mensch
, (© APA-Fotoservice für CIRA. Mit freundlicher Genehmigung der CIRA.) >> Öffnen auf photaq.com
Aktien auf dem Radar:Addiko Bank, Immofinanz, Wienerberger, Flughafen Wien, Warimpex, Porr, AT&S, Palfinger, Strabag, Uniqa, Verbund, Pierer Mobility, Andritz, Frequentis, S Immo, Oberbank AG Stamm, Amag, Agrana, CA Immo, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, VIG.
Valneva
Valneva ist ein Impfstoffunternehmen, das sich auf die Entwicklung und Vermarktung von prophylaktischen Impfstoffen gegen Infektionskrankheiten mit hohem ungedeckten medizinischen Bedarf spezialisiert hat.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER